Key Documents

View All Documentation

N3136

Naltrexone hydrochloride

Name: Naltrexone hydrochloride
Brand: SIGMA

≥99% (HPLC), powder, opioid receptor antagonist

Synonym(s):

Naltrexone HCl

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₂₀H₂₃NO₄ · HCl

CAS Number:

16676-29-2

Molecular Weight:

377.86

NACRES:

NA.77

PubChem Substance ID:

24278051

UNSPSC Code:

12352200

EC Number:

240-723-0

MDL number:

MFCD00069324

Beilstein/REAXYS Number:

3580333

Form:

powder

Quality level:

100

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Product Name

Naltrexone hydrochloride,

form

powder

Quality Level

100

originator

Novartis

storage temp.

2-8°C

SMILES string

Cl.Oc1ccc2C[C@H]3N(CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O)CC6CC6

InChI

1S/C20H23NO4.ClH/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11;/h3-4,11,15,18,22,24H,1-2,5-10H2;1H/t15-,18+,19+,20-;/m1./s1

InChI key

RHBRMCOKKKZVRY-ITLPAZOVSA-N

Gene Information

human ... OPRD1(4985), OPRK1(4986), OPRM1(4988), OPRS1(10280)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Bioactive Small Molecules

Application

Naltrexone hydrochloride has been used:

as an opioid antagonist, to analyse its effect on ethanol preference using Caenorhabditis elegans as a model
to determine its effectiveness in reducing the preference for substance of abuse (SOA) like nicotine and cocaine using Caenorhabditis elegans as a model
in the preparation of combinatorial drug, PXT3003 for treating Charcot-Marie-Tooth disease 1A (CMT1A) transgenic rat model Pmp22

Biochem/physiol Actions

Competitive antagonist for μ, κ, δ, and σ-opioid receptors; has greater oral efficacy and longer duration of action than naloxone.

Features and Benefits

This compound is featured on the Opioid Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

GHS07

signalword

Warning

hcodes

H302

pcodes

P264 - P270 - P301 + P312 - P501

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

Regulatory Information

涉药品监管产品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Development and validation of a bioanalytical method for the simultaneous determination of heroin, its main metabolites, naloxone and naltrexone by LC-MS/MS in human plasma samples: Application to a clinical trial of oral administration of a heroin/naloxone formulation.

Raquel Moreno-Vicente et al.

Journal of pharmaceutical and biomedical analysis, 114, 105-112 (2015-06-04)

A bioanalytical method using high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) was developed and validated for simultaneous quantification of heroin, its main metabolites and naloxone. In addition, naltrexone was detected qualitatively. This method was used to analyse human plasma samples from

Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A)

Prukop T, et al.

Testing, 14(1), e0209752-e0209752 (2019)

Caenorhabditis elegans show preference for stimulants and potential as a model organism for medications screening

Engleman EA, et al.

Frontiers in Physiology, 9, 7-16 (2018)

Behavioural profile of exendin-4/naltrexone dose combinations in male rats during tests of palatable food consumption.

F L Wright et al.

Psychopharmacology, 231(18), 3729-3744 (2014-04-01)

The glucagon-like peptide 1 receptor (GLP-1R) agonist exendin-4 potently suppresses food intake in animals and humans. However, little is known about the behavioural specificity of this effect either when administered alone or when co-administered with another anorectic agent. The present

Caenorhabditis elegans as a model system to identify therapeutics for alcohol use disorders.

Simon N Katner et al.

Behavioural brain research, 365, 7-16 (2019-02-26)

Alcohol use disorders (AUDs) cause serious problems in society and few effective treatments are available. Caenorhabditis elegans (C. elegans) is an excellent invertebrate model to study the neurobiological basis of human behavior with a conserved, fully tractable genome, and a

View All Related Papers

Global Trade Item Number

SKU	GTIN
N3136-250MG	04061832557502
N3136-100MG	04061834115809
N3136-1G	04061826203408

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service